Andrea Snow‐Lampart

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

M. Manns, M. Washington, M. Buti, 2008, The New England journal of medicine.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Huy Trinh, Robert Flisiak, Franck Rousseau, 2011, Gastroenterology.

Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.

P. Marcellin, M. Shiffman, Ting Chang, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

M1923 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV)

P. Marcellin, K. Borroto-Esoda, F. Rousseau, 2008 .

76 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN SUBJECTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (ADV)

T. Berg, P. Marcellin, K. Borroto-Esoda, 2008 .

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

Katyna Borroto-Esoda, P. Marcellin, K. Kitrinos, 2011, Hepatology.